Abstract:Various targets, such as estrogen receptor (ER), mammalian target ofrapamycin(mTOR), epidermal growth factor receptor (EGFR), androgen receptor (AR) andpoly adenosine diphosphate-ribose polymerase (PARP), are focused on the treatment of breast cancer. In this study, in silico tools such as pharmacophore modeling, 3D QSAR study, molecular docking, binding free energy determination and molecular dynamics were executed on a series of pyrazolopyrimidines derivatives. The pharmacophore modeling of forty-one anticancer derivatives was generated, and atom-based 3D QSAR was applied. Molecular docking, dynamics, binding energy and high-throughput virtual screening (HTVS) were conducted by the software Schrodinger. The best five featured pharmacophore hypotheses AHRRR_1 with a maximum survival score of 5.533 was subjected to rigorous scoring function analysis and 3D QSAR studies. Docking studies and binding free energy were carried out on 41 inhibitors for their anti-breast cancer activity against human estrogen, progesterone receptor, EGFR kinase and mammalian target of rapamycin mTOR. Molecular dynamics simulation of the docked complex-34/4WKQ validated the stability of this complex. HTVS was performed to determine the virtual hits with the best-fitted model AHRRR_1. New EGFR kinase inhibitors were designed based on the active compound templates. Molecular docking was carried out on virtual hits, and newly designed compounds and dynamics studies revealed that the binding modes obtained after MD simulation were more or less similar to that acquired post docking mode. Promiscuity assessments demonstrated that designed compounds would be specific rather than a promiscuous one. Based on these findings, we have designed four novel compounds as anti-breast inhibitors, with potent binding affinity and desirable ADME properties.

Pharmacophore Model Analysis Of Novel Tyrphostins

Common Pharmacophore Model and 3D-QSAR Analysis of Two Different Tyrphostin Families

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Pharmacophore Model Construction of β-Secretase Inhibitors

Pharmacophore Model and 3D-QSAR Study of Two Kinds of HCVNS3 Serine Protease Inhibitors

Pharmacophore model construction of beta-secretase inhibitors

Pharmacophore Modeling Study Based on Known Spleen Tyrosine Kinase Inhibitors Together with Virtual Screening for Identifying Novel Inhibitors.

Combined Structure-Based Pharmacophore And 3d-Qsar Studies On Phenylalanine Series Compounds As Tph1 Inhibitors

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Pharmacophore Modeling Studies of Type I and Type II Kinase Inhibitors of Tie2.

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors

Development of Novel Selective Pharmacophore for Tankyrase Inhibitors

Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors

Screening from Tcm Database@Taiwan and Qsar Model for Identifying Her2 Inhibitors

3D-QSAR, molecular docking, and new compound design of pyrimidine derivatives as Src small molecule inhibitors

Dual-Targeted Drug Design Of Her2 And Hsp90 By Comfa Model And Pharmacophore Analysis

Structure-based and ligand-based drug design for HER 2 receptor.

Toll-like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies.

Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors